Sabby Management Has Boosted By $4.61 Million Its United Therapeutics (UTHR) Position; Insulet (PODD)’s Sentiment Is 1.2

December 7, 2017 - By Vivian Currie

Sabby Management Llc increased United Therapeutics Corp (UTHR) stake by 206.29% reported in 2017Q2 SEC filing. Sabby Management Llc acquired 35,774 shares as United Therapeutics Corp (UTHR)’s stock declined 27.66%. The Sabby Management Llc holds 53,116 shares with $6.89M value, up from 17,342 last quarter. United Therapeutics Corp now has $5.87B valuation. The stock increased 1.12% or $1.5 during the last trading session, reaching $135.74. About 92,464 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has risen 9.78% since December 7, 2016 and is uptrending. It has underperformed by 6.92% the S&P500.

Insulet Corporation, a medical device company, develops, makes, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company has market cap of $4.04 billion. The firm offers Omnipod Insulin Management System , which consists of the OmniPod, an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device. It currently has negative earnings. It also customizes the Omnipod System technology platform for the delivery of subcutaneous drugs across various therapeutic areas.

Slate Path Capital Lp holds 5.45% of its portfolio in Insulet Corporation for 2.80 million shares. Shaker Investments Llc Oh owns 81,300 shares or 3.15% of their US portfolio. Moreover, Valinor Management L.P. has 2.68% invested in the company for 1.71 million shares. The New York-based Tirschwell & Loewy Inc has invested 2.45% in the stock. Dafna Capital Management Llc, a California-based fund reported 63,484 shares.

The stock increased 0.86% or $0.6 during the last trading session, reaching $69.39. About 224,860 shares traded. Insulet Corporation (PODD) has risen 48.83% since December 7, 2016 and is uptrending. It has outperformed by 32.13% the S&P500.

Analysts await Insulet Corporation (NASDAQ:PODD) to report earnings on February, 26. They expect $-0.07 earnings per share, up 56.25% or $0.09 from last year’s $-0.16 per share. After $-0.04 actual earnings per share reported by Insulet Corporation for the previous quarter, Wall Street now forecasts 75.00% negative EPS growth.

Ratings analysis reveals 100% of Insulet’s analysts are positive. Out of 2 Wall Street analysts rating Insulet, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $47.0 while the high is $50.0. The stock’s average target of $48.50 is -30.11% below today’s ($69.39) share price. PODD was included in 2 notes of analysts from January 6, 2017. The firm earned “Outperform” rating on Tuesday, February 28 by Wedbush. The stock has “Outperform” rating by Robert W. Baird on Friday, January 6.

Since June 8, 2017, it had 0 buys, and 1 sale for $161,193 activity. Another trade for 1,240 shares valued at $160,699 was sold by ROTHBLATT MARTINE A.

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 4 Sell and 6 Hold. Therefore 17% are positive. United Therapeutics had 25 analyst reports since July 29, 2015 according to SRatingsIntel. On Tuesday, November 29 the stock rating was downgraded by Barclays Capital to “Underweight”. The stock of United Therapeutics Corporation (NASDAQ:UTHR) earned “Hold” rating by Argus Research on Tuesday, May 24. The rating was maintained by H.C. Wainwright on Thursday, October 26 with “Hold”. As per Thursday, December 15, the company rating was initiated by Oppenheimer. H.C. Wainwright downgraded it to “Neutral” rating and $95 target in Wednesday, June 15 report. The rating was maintained by Cowen & Co with “Outperform” on Monday, August 17. The rating was maintained by Cowen & Co on Thursday, July 27 with “Hold”. The firm has “Buy” rating by Oppenheimer given on Sunday, July 30. The rating was maintained by Oppenheimer with “Buy” on Tuesday, July 18. Jefferies maintained United Therapeutics Corporation (NASDAQ:UTHR) on Tuesday, June 6 with “Sell” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By :